Tvardi Therapeutics Inc (TVRD) Stock Price, Quote & News - Mboum

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 489 8654

Website: tvarditherapeutics.com

Address:

3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States

BigTimePennyStocks Aug. 16 at 9:44 PM

Small-Caps with Catalysts this week: 👇👇 ( $SRFM, $SURG, $TVRD, $NEXR, $LGHL, etc...) #NASDAQ #NYSE

1 · Reply

StocktwitsEarnings Aug. 14 at 6:00 PM

$TVRD Q2 '26 Earnings Results & Recap Tvardi Therapeutics, Inc. reported a net loss of $6.5 million for the three months ended June 30, 2026, with cash and cash equivalents totaling $15.8 million as of that date.

0 · Reply

kule04 Aug. 11 at 11:16 AM

$TVRD What's been going on here?

0 · Reply

buylowhope Aug. 6 at 1:48 PM

$TVRD option markets are to wide they suck.

0 · Reply

STACKD0E Jul. 30 at 11:57 AM

$DRIO $MOB $TVRD ✨️

0 · Reply

Fakhrul123 Jul. 30 at 10:03 AM

0 · Reply

Kplt1972 Jul. 28 at 4:51 PM

$TVRD get out while you can

0 · Reply

graniterock Jul. 23 at 6:17 PM

$TVRD I've just started buying some of this waiting for the results of phase 2 ,no doubt the upgrades are in lieu of great results whenever they may be posted. Does anyone follow this closely and when might we expect some words from the company thx

0 · Reply

Kplt1972 Jul. 23 at 3:49 PM

$TVRD zero

0 · Reply

Etiqute Jul. 23 at 12:36 PM

$TVRD Key Pipeline Catalysts (2026) TTI-109 Progression: Following positive Phase 1 tolerability data in July, Tvardi plans to advance this oral STAT3 inhibitor into clinical trials for dermatologic and gastrointestinal diseases. [1] TTI-101 Data: Topline data from the Phase 1b/2 trial of TTI-101 targeting hepatocellular carcinoma (liver cancer) is on track to release in the second half of 2026. [1, 2] Cash Runway: The company reports $25 million in cash as of its last audit, which it expects will fund operations through these crucial clinical readouts into Q4 2026. [1]

0 · Reply

Latest News on TVRD

Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)

2026-08-16T13:43:56.000Z - 3 days ago

Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Jul 30, 2026, 7:30 AM EDT - 20 days ago

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data

2026-07-08T19:40:46.000Z - 5 weeks ago

Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data

Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler

2026-07-08T19:35:10.000Z - 5 weeks ago

Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler

Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James

2026-07-08T09:45:22.000Z - 6 weeks ago

Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James

Tvardi Therapeutics announces positive Phase 1 results for TTI-109

2026-07-07T13:10:23.000Z - 6 weeks ago

Tvardi Therapeutics announces positive Phase 1 results for TTI-109

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-08T10:20:08.000Z - 2 months ago

Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026, 8:00 AM EDT - 3 months ago

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

2026-05-08T11:14:39.000Z - 3 months ago

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

May 8, 2026, 7:00 AM EDT - 3 months ago

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics files $200M mixed securities shelf

2026-05-01T20:11:24.000Z - 3 months ago

Tvardi Therapeutics files $200M mixed securities shelf

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

2026-04-20T09:26:43.000Z - 4 months ago

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

2026-04-01T11:13:02.000Z - 5 months ago

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

2026-04-01T10:34:44.000Z - 5 months ago

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

2026-03-31T20:06:37.000Z - 5 months ago

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Mar 31, 2026, 4:01 PM EDT - 5 months ago

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

2026-02-04T11:11:35.000Z - 7 months ago

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 7 months ago

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

2026-01-08T13:25:58.000Z - 7 months ago

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 9 months ago

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

2025-11-13T21:06:01.000Z - 9 months ago

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 9 months ago

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 10 months ago

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

2025-10-13T20:15:10.000Z - 11 months ago

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

2025-10-13T14:35:06.000Z - 11 months ago

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-13T14:15:14.000Z - 11 months ago

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Oct 13, 2025, 7:30 AM EDT - 11 months ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

May 6, 2025, 7:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

BigTimePennyStocks Aug. 16 at 9:44 PM

Small-Caps with Catalysts this week: 👇👇 ( $SRFM, $SURG, $TVRD, $NEXR, $LGHL, etc...) #NASDAQ #NYSE

1 · Reply

StocktwitsEarnings Aug. 14 at 6:00 PM

$TVRD Q2 '26 Earnings Results & Recap Tvardi Therapeutics, Inc. reported a net loss of $6.5 million for the three months ended June 30, 2026, with cash and cash equivalents totaling $15.8 million as of that date.

0 · Reply

kule04 Aug. 11 at 11:16 AM

$TVRD What's been going on here?

0 · Reply

buylowhope Aug. 6 at 1:48 PM

$TVRD option markets are to wide they suck.

0 · Reply

STACKD0E Jul. 30 at 11:57 AM

$DRIO $MOB $TVRD ✨️

0 · Reply

Fakhrul123 Jul. 30 at 10:03 AM

0 · Reply

Kplt1972 Jul. 28 at 4:51 PM

$TVRD get out while you can

0 · Reply

graniterock Jul. 23 at 6:17 PM

$TVRD I've just started buying some of this waiting for the results of phase 2 ,no doubt the upgrades are in lieu of great results whenever they may be posted. Does anyone follow this closely and when might we expect some words from the company thx

0 · Reply

Kplt1972 Jul. 23 at 3:49 PM

$TVRD zero

0 · Reply

Etiqute Jul. 23 at 12:36 PM

$TVRD Key Pipeline Catalysts (2026) TTI-109 Progression: Following positive Phase 1 tolerability data in July, Tvardi plans to advance this oral STAT3 inhibitor into clinical trials for dermatologic and gastrointestinal diseases. [1] TTI-101 Data: Topline data from the Phase 1b/2 trial of TTI-101 targeting hepatocellular carcinoma (liver cancer) is on track to release in the second half of 2026. [1, 2] Cash Runway: The company reports $25 million in cash as of its last audit, which it expects will fund operations through these crucial clinical readouts into Q4 2026. [1]

0 · Reply

Etiqute Jul. 23 at 12:36 PM

$TVRD Analyst Ratings and Price Targets Consensus Rating: Balanced at a Moderate Buy across major firms. Average Price Target: Settles around $19.67, though recent targets after the trial data sit closer to $10.00. Recent Upgrades: Piper Sandler upgraded the stock to Overweight, and Raymond James set a $10 price target. [1, 2, 3]

1 · Reply

Etiqute Jul. 23 at 12:35 PM

$TVRD 7 sites Tvardi Therapeutics (TVRD) stock is trading around $2.70 following positive Phase 1 clinical trial results for its drug TTI-109, an upgraded analyst rating, and upcoming second-quarter earnings. Yahoo Finance +3 Recent Clinical and Financial Updates Phase 1 Trial Success: Reported positive Phase 1 results for TTI-109 (an oral STAT3 inhibitor for inflammatory diseases) showing improved tolerability. Analyst Action: Raymond James upgraded the stock to an Outperform rating with a $10 price target. Upcoming Earnings: Q2 2026 financial results are expected around August 13, 2026. Prior Volatility: The stock previously faced heavy losses in late 2025 after a Phase 2 fibrosis study missed primary goals.

0 · Reply

Kplt1972 Jul. 20 at 11:39 PM

$TVRD salvage some pennies now before it goes to zero

0 · Reply

Kplt1972 Jul. 20 at 1:44 PM

$TVRD zero soon

0 · Reply

focafoca99 Jul. 17 at 8:16 PM

$TVRD increased its at-the-market offering to up to $9.69 million.

0 · Reply

Kplt1972 Jul. 17 at 5:05 PM

$TVRD zero soon Out of cash. Nothing close to being FDA approved for years.

0 · Reply

Stock_Catcher Jul. 17 at 2:05 PM

$TVRD Continuation

0 · Reply

lilbylil Jul. 17 at 11:21 AM

$TVRD Uptrend and recent upgrades, lets Gooooooo!!!! 💪🏻 🚀

0 · Reply

Dirtdemon75 Jul. 15 at 9:18 PM

0 · Reply

Kplt1972 Jul. 14 at 6:36 PM

$TVRD zero soon

0 · Reply

lilbylil Jul. 14 at 5:58 PM

0 · Reply

Kplt1972 Jul. 14 at 2:25 PM

$TVRD zero soon

0 · Reply